NCX 1022

Identification

Name
NCX 1022
Accession Number
DB05410
Type
Small Molecule
Groups
Investigational
Description

NCX is an NO-releasing derivative of hydrocortisone.

Structure
Thumb
Synonyms
Not Available
External IDs
NCX 1022 / NCX-1022
Categories
UNII
Not Available
CAS number
571186-50-0
Weight
Average: 541.597
Monoisotopic: 541.231181711
Chemical Formula
C29H35NO9
InChI Key
MBODWAULVMWNDB-UHFFFAOYSA-N
InChI
InChI=1S/C29H35NO9/c1-27-10-8-20(31)13-19(27)6-7-21-22-9-11-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-4-17(12-18)15-39-30(36)37/h3-5,12-13,21-23,25,32,35H,6-11,14-16H2,1-2H3
IUPAC Name
SMILES
CC12CC(O)C3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C(=O)COC(=O)C1=CC=CC(CON(=O)=O)=C1

Pharmacology

Indication

Investigated for use/treatment in atopic dermatitis.

Pharmacodynamics
Not Available
Mechanism of action

NCX 1022 is designed to have potent anti- inflammatory activity combined with a significantly improved safety and tolerability profile, in particular the absence of skin blanching after repeated use.It is better than hydrocortisone in terms of inhibiting benzalkonium chloride-induced leukocyte adhesion to the endothelium, without affecting the flux of rolling leukocytes or venule diameter.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with NCX 1022.
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with 1,10-Phenanthroline.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with NCX 1022.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with NCX 1022.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with NCX 1022.
AlmasilateThe bioavailability of NCX 1022 can be decreased when combined with Almasilate.
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with NCX 1022.
AloglutamolThe bioavailability of NCX 1022 can be decreased when combined with Aloglutamol.
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with NCX 1022.
AluminiumThe bioavailability of NCX 1022 can be decreased when combined with Aluminium.
Food Interactions
Not Available

References

General References
  1. Hyun E, Bolla M, Steinhoff M, Wallace JL, Soldato PD, Vergnolle N: Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25. Epub 2004 Aug 16. [PubMed:15313880]
External Links
PubChem Substance
347910124

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:24 / Updated on October 01, 2018 14:01